Therapy Directory

Ipilimumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Ipilimumab as a study intervention. Browse Ipilimumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:51 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

640

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Prostate Cancer
Interventions: Ipilimumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: encorafenib, nivolumab, ipilimumab, binimetinib; Drug
Lead sponsor: Jason J. Luke, MD; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Liver Metastases, Lung Metastases, Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
Interventions: ipilimumab, stereotactic radiosurgery, laboratory biomarker analysis; Biological · Radiation · Other
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Mesothelioma
Interventions: Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 605 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 14
States / cities: San Francisco, California • New Haven, Connecticut • Tampa, Florida + 11 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Springdale, Arkansas • New Haven, Connecticut • Jacksonville, Florida + 6 more

Conditions: Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Interventions: Envafolimab, Ipilimumab; Biological · Drug
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 207 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 29
States / cities: Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more

Conditions: Melanoma
Interventions: Talimogene laherparepvec, Ipilimumab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 32
States / cities: Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 24 more

Conditions: Metastatic Cancer
Interventions: Keytruda Injectable Product, Yervoy Injectable Product, Cytoxan, Cryosurgical freezing (cryosurgery), GM-CSF Injectable; Drug · Procedure
Lead sponsor: Rampart Health, L.L.C.; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester, Michigan

Conditions: Melanoma
Interventions: Nivolumab, Ipilimumab; Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 16 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Cell Carcinoma, Renal Cell Carcinoma Stage IV
Interventions: Nivolumab, Ipilimumab, bland embolization; Drug · Device
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Advanced Melanoma, Metastatic Melanoma
Interventions: Nivolumab, Ipilimumab; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 12
States / cities: Los Angeles, California • Chicago, Illinois • Lutherville, Maryland + 7 more

Conditions: Melanoma
Interventions: Nivolumab +/- ipilimumab, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Up to 18 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Dublin, Ohio

About this Ipilimumab clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Ipilimumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results: Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Ipilimumab.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Ipilimumab clinical trials

Filter and sort this therapy

Live official records

T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer

Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma

A Phase 2 Trial for Patients With Metastatic Solid Cancer

Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma

Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma

About this Ipilimumab clinical trials directory page